Peter Martin, MD
Weill Medical College of Cornell University
6
6
4
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+9 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Julie Vose, MD
University of Nebraska
Shared therapeutic areas:
Worked with same sponsors:
Jonathan Friedberg, MD
University of Rochester James P. Wilmot Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Anas Younes, MD
MD Anderson Cancer Center at University of Texas, Houston
Shared therapeutic areas:
Worked with same sponsors:
Richard Klasa, MD
British Columbia Cancer Center - Vancouver Centre
Shared therapeutic areas:
Worked with same sponsors:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Arnon Nagler, MD
Chaim Sheba Medical Center
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Roberto Hernández Martín, MD
Hospital Virgen de la Concha
Shared therapeutic areas:
Elena Pérez Ceballos, MD
Hospital Morales Meseguer
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)
Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
All 6 trials loaded